Fast Five Quiz: Treatment in Relapsed Multiple Sclerosis

Kerstin Hellwig, MD; Christopher Luzzio, MD


November 22, 2022

According to guidelines from the American Academy of Neurology (AAN), which were published in 2018, when patients with MS are stable (no relapses, no disability progression, stable imaging), continuation of their current DMT is recommended unless the patient and physician jointly decide to initiate a trial off therapy. When stopping treatment, joint guidelines from the European Committee For Treatment And Research In Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology (EAN), also published in 2018, urge clinicians and patients to consider the possibility of resumed disease activity or even rebound. There are limited data to support decision-making when it comes to discontinuing DMT, but randomized controlled trials are underway. Some studies have shown that when patients go off DMT, those most likely to experience recurrence are relatively younger, have had recent disease activity clinically with a relapse, and have had a recent active lesion on their scan.

Learn more about DMT for MS.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.